LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

44.77 4.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

42.73

Максимум

44.77

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.22% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	71M 3.3B
Предишно отваряне	40
Предишно затваряне	44.77

Настроения в новините

By Acuity

50%

161 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.02.2026 г., 23:07 ч. UTC

Печалби

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 23:01 ч. UTC

Печалби

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:59 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24.02.2026 г., 22:42 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24.02.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24.02.2026 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24.02.2026 г., 23:30 ч. UTC

Пазарно говорене

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.02.2026 г., 23:16 ч. UTC

Печалби

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24.02.2026 г., 23:13 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24.02.2026 г., 23:12 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24.02.2026 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24.02.2026 г., 23:07 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24.02.2026 г., 22:52 ч. UTC

Печалби

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 22:46 ч. UTC

Печалби

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Warner Receives New Bid From Paramount -- 3rd Update

24.02.2026 г., 22:29 ч. UTC

Печалби

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24.02.2026 г., 22:28 ч. UTC

Печалби

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24.02.2026 г., 22:25 ч. UTC

Печалби

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24.02.2026 г., 22:24 ч. UTC

Печалби

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24.02.2026 г., 22:23 ч. UTC

Печалби

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths Interim Dividend 45 Australian Cents/Share

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24.02.2026 г., 22:21 ч. UTC

Печалби

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

30.22% нагоре

12-месечна прогноза

Среден 55.63 USD 30.22%

Висок 66 USD

Нисък 44 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

161 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.